Articles related to SCHIZOPHRENIA

Anxiety disorders are among the most common of psychiatric disorders, with estimates suggesting a lifetime prevalence in the US of approximately 32%. But development of new and effective treatments for anxiety disorders has lagged behind new treatments for other conditions such as major depressive disorder, bipolar disorder, and schizophrenia. This article reviews current treatment and their effectiveness, and highlights the emerging new hopefuls.

The authors concluded that, after reviewing the 13-year-study, “switching to LAIs during the first 3 years of treatment improved antipsychotic adherence, decreased relapses, and reduced long-term mortality.” With few studies available comparing the long-term effectiveness between patients who switched to LAIs and those who remained on oral antipsychotics (OAPs), they hope the evidence presented supports the benefits of early LAI treatment in schizophrenia.